Search - tctmd.com

Displaying 61 - 80 of 728

Sort: Relevancy | Date

Intermediate Disease May Be the ‘Sweet Spot’ for T-TEER Survival Benefit

News Daily News

Intermediate Disease May Be the ‘Sweet Spot’ for T-TEER Survival Benefit

Yael L. Maxwell

February 12, 2025

Surgeons: Be Active in Tricuspid Procedures or Be ‘Left Behind’

News Conference News STS 2025

Surgeons: Be Active in Tricuspid Procedures or Be ‘Left Behind’

Yael L. Maxwell

February 05, 2025

Presentation Miami Valves 2025

Novel TMVR Devices: CAPSTAN Medical

Presenter: Santiago Garcia

January 30, 2025

Amid Declining Use, Mechanical SAVR Valves Beat Bioprosthetic for Survival

News Conference News STS 2025

Amid Declining Use, Mechanical SAVR Valves Beat Bioprosthetic for Survival

Yael L. Maxwell

January 27, 2025

TCTMD’s Biggest News of 2024: Stories, Videos, and More

News Opinion Editor's Corner

TCTMD’s Biggest News of 2024: Stories, Videos, and More

January 01, 2025

Top Structural Heart News of 2024

News Daily News

Top Structural Heart News of 2024

December 29, 2024

Downsizing, Underexpansion Common in Redo TAVI With Sapien 3

News Daily News

Downsizing, Underexpansion Common in Redo TAVI With Sapien 3

December 20, 2024

December 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

December 2024 Dispatch for the CV Team

December 20, 2024

Sustained Benefit With Pascal TEER Device at 2 Years: CLASP IID and MiCLASP

News Conference News PCR London Valves 2024

Sustained Benefit With Pascal TEER Device at 2 Years: CLASP IID and MiCLASP

Michael O'Riordan

December 05, 2024

Newest Sapien TAVI Equals Surgery in Patients With Small Aortic Annuli at 5 Years

News Conference News PCR London Valves 2024

Newest Sapien TAVI Equals Surgery in Patients With Small Aortic Annuli at 5 Years

Michael O'Riordan

November 27, 2024

Residual TR After Treating Mitral ViV Disease Linked to Worse Outcomes

News Conference News PCR London Valves 2024

Residual TR After Treating Mitral ViV Disease Linked to Worse Outcomes

Michael O'Riordan

November 26, 2024

November 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

November 26, 2024

Closing the Left Atrial Septal Pouch For Stroke Prevention Explored in Small Trial

News Daily News

Closing the Left Atrial Septal Pouch For Stroke Prevention Explored in Small Trial

November 25, 2024

Live Valve Cases Safe, With Outcomes Comparable to Trials and Practice

News Conference News PCR London Valves 2024

Live Valve Cases Safe, With Outcomes Comparable to Trials and Practice

Michael O'Riordan

November 25, 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

News Conference News AHA 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

November 18, 2024

Percutaneous Mechanical Aspiration Promising for Right-Heart Infective Endocarditis

News Conference News TCT 2024

Percutaneous Mechanical Aspiration Promising for Right-Heart Infective Endocarditis

November 08, 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

November 01, 2024

Embolic Protection Benefits Varied by Geography in PROTECTED TAVR

News Conference News TCT 2024

Embolic Protection Benefits Varied by Geography in PROTECTED TAVR

October 31, 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

News Conference News TCT 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

Michael O'Riordan

October 30, 2024

One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial

Presentation TCT 2024

One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial

Presenter: Michael Reardon

October 30, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.